Clinical outcomes | Comparisons | Therapy type | Illustrative comparative risk | Relative effect (95% CI) | No. of participants (studies) | Quality of evidence (GRADE) | |
---|---|---|---|---|---|---|---|
With comparator | With intervention | ||||||
Asthma exacerbation | Zafirlukast vs. placebo | First-line | 92/1000 | 62/1000 (44 to 92) | OR = 0.68 [0.45, 1.00] | 1,255 (n = 4) | ⊕ ⊕ ⊝⊝ Low1 |
Zafirlukast vs. ICs | First-line | 31/1000 | 64/1000 (42 to 96) | OR = 2.11 [1.35, 3.30] | 1,963 (n = 6) | ⊕ ⊕ ⊕⊝ Moderate2 | |
Zafirlukast vs. ICs | Add-on | 83/1000 | 92/1000 (46 to 175) | OR = 1.12 [0.53, 2.34] | 353 (n = 2) | ⊕ ⊕ ⊝⊝ Low3 | |
Zafirlukast vs. placebo | Add-on | 121/1000 | 120/1000 (69 to 200) | OR = 0.96 [0.54, 1.81] | 383 (n = 3) | ⊕ ⊕ ⊝⊝ Low4 | |
Asthma exacerbation requiring systemic corticosteriod | Zafirlukast vs. placebo | First-line | 108/1000 | 86/1000 (40 to 186) | OR = 0.76 [0.45, 1.29] | 544 (n = 2) | ⊕ ⊕ ⊝⊝ Low5 |
Zafirlukast vs. ICs | First-line | 18/1000 | 64/1000 (32 to 123) | OR = 3.71 [1.82, 7.59] | 1,089 (n = 3) | ⊕ ⊕ ⊕⊝ Moderate6 | |
Asthma exacerbation requiring emergency treatment | Zafirlukast vs. ICs | First-line | 22/1000 | 23/1000 (10 to 53) | OR = 1.07 [0.46, 2.51] | 994 (n = 3) | ⊕ ⊕ ⊝⊝ Low7 |
Zafirlukast vs. placebo | Add-on | 60/1000 | 44/1000 (11 to 159) | OR = 0.72 [0.18, 2.99] | 163 (n = 3) | ⊕ ⊕ ⊝⊝ Low8 |